A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus
Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE 811)
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other exclusion criteria may apply.